BioPharmSignal logoBioPharmSignal

Biotech News

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Aligos Therapeutics (ALGS)Aligos TherapeuticsEarnings

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and

Open original release

Related news

ALGSAligos Therapeutics2026-05-07 20:06 EST

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

ALGSAligos Therapeutics2026-04-30 20:05 EST

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

MLYSMineralys Therapeutics2026-03-09 12:00 EST

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

MLYSMineralys Therapeutics2026-03-12 20:05 EST

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-04-29 20:05 EST

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-07-22 20:05 EST

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

VANIVivani Medical2026-03-26 20:16 EST

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MISTMilestone Pharmaceuticals Inc.2026-03-20 11:55 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

MISTMilestone Pharmaceuticals Inc.2026-03-12 12:00 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MNKDMannKind2026-02-26 13:00 EST

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

View all latest news

Aligos Therapeutics

Aligos Therapeutics is a biotechnology company focused on liver disease, virology, and cardiometabolic targets. Its pipeline is centered on difficult diseases with a need for differentiated small-molecule science.

Recent company news

ALGSAligos Therapeutics2026-05-27 06:30 EST

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

ALGSAligos Therapeutics2026-05-07 20:06 EST

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

ALGSAligos Therapeutics2026-04-30 20:05 EST

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

ALGSAligos Therapeutics2026-04-24 12:00 EST

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
4.08 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States